Aardvark Therapeutics (AARD) vs Immutep (IMMP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Immutep (IMMP) has outperformed Aardvark Therapeutics (AARD) over the past year, gaining 80.8% versus a loss of 90.2%. Immutep is the larger company by market cap ($22.9 million vs $20.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AARD | IMMP |
|---|---|---|
| Share price | $0.9226 | $3.11 |
| Market cap | $20.20M | $22.92M |
| 1-day change | -7.74% | -9.06% |
| YTD return | -92.97% | +8.74% |
| 1-year return | -90.15% | +80.81% |
| 5-year return | — | -8.53% |
| EPS (TTM) | $-3.33 | $-7.30 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | — |
| Net income (latest FY) | $-57.59M | — |
| 52-week high | $16.60 | $70.60 |
| 52-week low | $0.90 | $2.66 |
| Distance from 52-week high | -94.44% | -95.59% |
| Analyst consensus | buy | none |
| Avg. price target upside | +1104.21% | +864.63% |
| Average volume | 643.53K | 26.07K |
| Shares outstanding | 21.89M | 7.37M |
| Employees | 28 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMMP has outperformed AARD by 171.0 percentage points over the past year.
About Aardvark Therapeutics
AARD stock →Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc.
Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees
About Immutep
IMMP stock →Immutep Limited, a clinical-stage biotechnology company, develops lymphocyte activation gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases in Australia. The company's lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on the LAG-3 immune control mechanism for the treatment of cancer.
Health Care · Biotechnology: Pharmaceutical Preparations
AARD vs IMMP FAQ
Which is bigger, Aardvark Therapeutics or Immutep?
Immutep (IMMP) is larger, with a market capitalization of $22.92M compared with $20.20M for Aardvark Therapeutics (AARD).
Which stock has performed better over the past year, AARD or IMMP?
IMMP returned +80.81% over the past 12 months, compared with -90.15% for AARD (price return, excluding dividends). Past performance does not predict future results.
Are Aardvark Therapeutics and Immutep in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.